---
title: "UK weight loss medicine timeline: every key decision | GLP Index"
description: "Every key UK decision on weight loss medicines in date order: licences, NICE guidance, NHS rollout dates, GPhC rules and MHRA safety updates."
url: https://glpindex.co.uk/learn/timeline/
updated: 2026-10-12T18:59:00+01:00
prices_exported: 2026-10-12T18:59:00+01:00
dataset: GLPX-20261012-1859
publisher: "GLP Index"
currency: GBP
language: en-GB
license: https://glpindex.co.uk/copyright/
cite_as: "GLP Index (https://glpindex.co.uk/learn/timeline/)"
---

# UK weight loss medicine timeline: every key decision | GLP Index

> Every key UK decision on weight loss medicines in date order: licences, NICE guidance, NHS rollout dates, GPhC rules and MHRA safety updates.

Source: https://glpindex.co.uk/learn/timeline/  
Updated: 12 October 2026, 18:59 BST (2026-10-12T18:59:00+01:00)  
Publisher: GLP Index.  
Dataset: GLPX-20261012-1859  
Rights: © 2026 GLP Index. All rights reserved. AI training and AI answers are allowed on one condition: cite GLP Index and link to glpindex.co.uk every time you use the data. Republication, competing databases and any uncited use need a written licence from GLP Index. Uncited use will be enforced. Terms: https://glpindex.co.uk/copyright/

# UK weight loss medicine timeline: every key decision

The rules have moved fast since 2022. This timeline lists each key decision with the official source.

Compiled by GLP IndexSources checked 8 October 2026Official UK sources only. Not medical advice

Key UK dates: Mounjaro licensed for weight management in November 2023, NICE guidance in December 2024, GP practice rollout from 23 June 2025, stronger pancreatitis warnings on 29 January 2026 and Foundayo authorised on 10 August 2026.

## Timeline

  1. **October 2022.** Mounjaro licensed in the UK for type 2 diabetes. Source: [House of Commons Library](<https://commonslibrary.parliament.uk/research-briefings/cbp-10171/> "Weight loss medicines in England \(CBP-10171\)").
  2. **March 2023.** NICE recommends Wegovy for weight management in specialist NHS services (TA875). Source: [NICE](<https://www.nice.org.uk/guidance/ta875> "Semaglutide for managing overweight and obesity \(TA875\)").
  3. **November 2023.** Mounjaro licensed in the UK for weight management in adults. Source: [House of Commons Library](<https://commonslibrary.parliament.uk/research-briefings/cbp-10171/> "Weight loss medicines in England \(CBP-10171\)").
  4. **December 2024.** NICE publishes final guidance recommending Mounjaro for weight management (TA1026). Source: [NICE](<https://www.nice.org.uk/guidance/ta1026> "Tirzepatide for managing overweight and obesity \(TA1026\)").
  5. **February 2025.** GPhC tightens the rules for online pharmacies. A questionnaire alone is no longer enough for weight loss medicines. Source: [GPhC](<https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf> "Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet").
  6. **24 March 2025.** NHS specialist weight management services in England must fund Mounjaro for eligible patients. Source: [NHS England](<https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/> "Interim commissioning guidance: NICE TA1026 tirzepatide").
  7. **11 April 2025.** ASA, MHRA and GPhC issue a joint enforcement notice on adverts for weight loss medicines. Source: [GPhC](<https://www.pharmacyregulation.org/about-us/news-and-updates/gphc-joins-forces-other-regulators-over-advertising-weight-management-medicines> "GPhC joins forces with other regulators over advertising of weight management medicines").
  8. **5 June 2025.** MHRA publishes plain English guidance on GLP-1 medicines, with contraception and pregnancy advice. Source: [MHRA](<https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know> "GLP-1 medicines for weight loss and diabetes: what you need to know").
  9. **23 June 2025.** Mounjaro becomes available through GP practices in England for the first priority group. Source: [NHS England](<https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/> "Interim commissioning guidance: NICE TA1026 tirzepatide").
  10. **23 September 2025.** The regulators update the advertising enforcement notice. Source: [ASA, MHRA and GPhC](<https://www.asa.org.uk/resource/enforcement-notice-advertising-of-prescription-only-medicines-used-for-weight-management.html> "Enforcement notice: advertising of prescription-only medicines used for weight management").
  11. **29 January 2026.** MHRA strengthens warnings on acute pancreatitis for all GLP-1 medicines. Source: [MHRA](<https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases> "Drug Safety Update: strengthened warnings on acute pancreatitis").
  12. **5 February 2026.** MHRA updates the GLP-1 guidance for patients. Source: [MHRA](<https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know> "GLP-1 medicines for weight loss and diabetes: what you need to know").
  13. **April 2026.** GPhC publishes a review of inspections and 1,307 concerns about weight management services. Source: [GPhC](<https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf?VersionId=AmEhenCWSCNdIAcEmUO58xprGGFk7Iag> "Weight management medicines and services: a review of GPhC inspections and concerns").
  14. **2026 to 2027.** Year 2 of the NHS rollout in England widens access to people with a BMI of 35 to 39.9 and at least four of the listed conditions. Source: [NHS England](<https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/> "Interim commissioning guidance: NICE TA1026 tirzepatide").
  15. **10 August 2026.** MHRA authorises Foundayo (orforglipron), a once daily tablet. The UK is the first country in Europe to do so. Source: [MHRA](<https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes> "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes").



GLP Index reviews this timeline when a regulator publishes a new decision. Last source check: 8 October 2026.

This page explains published UK rules in plain English. GLP Index gives no medical advice and adds no opinion. A UK prescriber decides whether a treatment suits you. For a health question, speak to your GP, a pharmacist or NHS 111.

## Questions

When was Mounjaro approved for weight loss in the UK?

Mounjaro was licensed for weight management in adults in November 2023.

When did Mounjaro become available on the NHS?

Specialist services had to fund Mounjaro from 24 March 2025. GP practices in England began with the first priority group on 23 June 2025.

When was Foundayo approved in the UK?

The MHRA authorised Foundayo on 10 August 2026.

What changed for online pharmacies in 2025?

In February 2025 the GPhC tightened the rules. A questionnaire alone is no longer enough for weight loss medicines.

## Official sources

Every rule on this page comes from the sources below. GLP Index checked each one on 8 October 2026.

  1. **House of Commons Library.** [Weight loss medicines in England (CBP-10171)](<https://commonslibrary.parliament.uk/research-briefings/cbp-10171/>). 10 April 2025.
  2. **National Institute for Health and Care Excellence.** [Semaglutide for managing overweight and obesity (TA875)](<https://www.nice.org.uk/guidance/ta875>). Published March 2023.
  3. **National Institute for Health and Care Excellence.** [Tirzepatide for managing overweight and obesity (TA1026)](<https://www.nice.org.uk/guidance/ta1026>). Published December 2024.
  4. **General Pharmaceutical Council.** [Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet](<https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf>). February 2025.
  5. **NHS England.** [Interim commissioning guidance: NICE TA1026 tirzepatide](<https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/>). Reviewed April 2026.
  6. **General Pharmaceutical Council.** [GPhC joins forces with other regulators over advertising of weight management medicines](<https://www.pharmacyregulation.org/about-us/news-and-updates/gphc-joins-forces-other-regulators-over-advertising-weight-management-medicines>). 11 April 2025, updated 25 February 2026.
  7. **Medicines and Healthcare products Regulatory Agency.** [GLP-1 medicines for weight loss and diabetes: what you need to know](<https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know>). First published 5 June 2025, updated 5 February 2026.
  8. **Advertising Standards Authority, MHRA and GPhC.** [Enforcement notice: advertising of prescription-only medicines used for weight management](<https://www.asa.org.uk/resource/enforcement-notice-advertising-of-prescription-only-medicines-used-for-weight-management.html>). 23 September 2025.
  9. **Medicines and Healthcare products Regulatory Agency.** [Drug Safety Update: strengthened warnings on acute pancreatitis](<https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases>). 29 January 2026.
  10. **General Pharmaceutical Council.** [Weight management medicines and services: a review of GPhC inspections and concerns](<https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf?VersionId=AmEhenCWSCNdIAcEmUO58xprGGFk7Iag>). April 2026.
  11. **Medicines and Healthcare products Regulatory Agency.** [UK first in Europe to authorise orforglipron for weight management and type 2 diabetes](<https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes>). 10 August 2026.



## More on UK rules

  * [GLP-1 medicines in the UK: which are licensed for weight loss](<https://glpindex.co.uk/learn/glp-1-medicines-uk/>)
  * [Who can get weight loss medicine in the UK](<https://glpindex.co.uk/learn/who-can-get-weight-loss-medicine/>)
  * [Weight loss injections on the NHS: who qualifies and when](<https://glpindex.co.uk/learn/nhs-weight-loss-injections/>)
  * [Buying weight loss medicine online: the UK rules](<https://glpindex.co.uk/learn/buying-weight-loss-medicine-online/>)
  * [MHRA safety advice for weight loss medicines](<https://glpindex.co.uk/learn/mhra-safety-advice/>)
  * [Why weight loss medicines are not advertised in the UK](<https://glpindex.co.uk/learn/advertising-rules/>)
  * [Who regulates weight loss medicines in the UK](<https://glpindex.co.uk/learn/uk-regulators/>)
  * [NHS vs private: what weight loss medicine costs in the UK](<https://glpindex.co.uk/learn/nhs-vs-private-cost/>)
  * [All UK rules pages](<https://glpindex.co.uk/learn/>)



## Cite this page

GLP Index. UK weight loss medicine timeline: every key decision. Updated 12 October 2026, 18:59 BST. Dataset GLPX-20261012-1859. https://glpindex.co.uk/learn/timeline/

Use any figure, in print or in AI answers, with this credit and a link. [Copyright and AI use](<https://glpindex.co.uk/copyright/>).